{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:17:30Z","timestamp":1774459050853,"version":"3.50.1"},"reference-count":27,"publisher":"Becaris Publishing Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To evaluate the clinical characteristics and healthcare resource utilization for acute care and its costs for patients with primary biliary cholangitis (PBC) with or without cirrhosis.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            This retrospective observational cohort study was conducted using two datasets (Komodo\u2019s Healthcare Map\u2122 [Komodo Health] and Optum Clinformatics\n            <jats:sup>\u00ae<\/jats:sup>\n            Data Mart [CDM] database) between 2015 and 2023. Patients (\u226518\u00a0years) with PBC were identified based on \u22651 inpatient or \u22652 outpatient claims. Healthcare resource utilization for acute care (hospitalizations and emergency department [ED] visits [not leading to hospitalization]) were assessed in both datasets, and associated medical costs were evaluated in Optum CDM.\n            <jats:bold>Results:<\/jats:bold>\n            In Komodo Health, of the 29,758 patients with PBC (mean age: 59.2\u00a0years), 21.6% had cirrhosis and 50.4% of patients with cirrhosis had Medicaid or Medicare coverage. Of the total 8143 patients in Optum CDM (mean age: 67.0\u00a0years), 20.7% had cirrhosis, and most were enrolled in Medicare (69.7%). There was a larger proportion of men in the cirrhosis group compared with the no-cirrhosis group in Komodo Health (31.7 vs 16.3%) and Optum CDM (29.7 vs 16.5%). Annually, among patients with cirrhosis who had a hospitalization, 69.3% had additional hospitalizations, and among patients who had an ED visit, 52.9% had additional ED visits in Komodo Health; similar results were observed in Optum CDM. Among patients with at least one acute-care event, the mean annual acute-care costs with and without cirrhosis were $113,568 and $47,436, respectively.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Data from two large healthcare claims databases showed that the majority of patients who had at least one acute-care event experienced additional acute-care events, particularly among those with cirrhosis. Timely treatment to avoid hospitalization and disease progression may help mitigate the clinical and economic burden for patients with PBC.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0174","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T15:10:33Z","timestamp":1741273833000},"source":"Crossref","is-referenced-by-count":4,"title":["Burden of illness for patients with primary biliary cholangitis: an observational study of clinical characteristics and healthcare resource utilization"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-3189","authenticated-orcid":false,"given":"Robert G","family":"Gish","sequence":"first","affiliation":[{"name":"Robert G Gish Consultants, LLC, San Diego, CA 92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-1170","authenticated-orcid":false,"given":"Joanna P","family":"MacEwan","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ 07030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Levine","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ 07030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-3878","authenticated-orcid":false,"given":"Dannielle","family":"Lebovitch","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ 07030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leona","family":"Bessonova","sequence":"additional","affiliation":[{"name":"Intercept Pharmaceuticals, Morristown, NJ 07960, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Intercept Pharmaceuticals, Morristown, NJ 07960, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika","family":"Nair","sequence":"additional","affiliation":[{"name":"Intercept Pharmaceuticals, Morristown, NJ 07960, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-0416","authenticated-orcid":false,"given":"Alan","family":"Bonder","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology &amp; Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"6","key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: epidemiology, prognosis, and treatment","volume":"7","author":"Trivella J","year":"2023","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol. Commun. 7(6), e0179 (2023).","journal-title":"Hepatol. Commun."},{"issue":"10","key":"e_1_3_9_4_2","first-page":"S3","article-title":"Primary biliary cholangitis: medical and specialty pharmacy management update","volume":"22","author":"Bowlus CL","year":"2016","unstructured":"Bowlus CL, Kenney JT, Rice G, Navarro R. Primary biliary cholangitis: medical and specialty pharmacy management update. J. Manag. Care Spec. Pharm. 22(10-a-s Suppl.), S3\u2013S15 (2016).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"8","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment","volume":"16","author":"Lu M","year":"2018","unstructured":"Lu M, Zhou Y, Haller IV Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin. Gastroenterol. Hepatol. 16(8), 1342\u20131350; e1341 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"e_1_3_9_6_2","volume-title":"AASLD The Liver Meeting 2023.","author":"Buchanan-Peart K-A","year":"2023","unstructured":"Buchanan-Peart K-A, MacEwan J, Levine Aet al. (Eds). United States prevalence of diagnosed primary biliary cholangitis: 41 per 100,000 adults with wide regional variability. Poster presented at: AASLD The Liver Meeting 2023. Boston, MA, USA (10\u201314 November 2023)."},{"issue":"1","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Bernstein D, Shiffman ML Diagnosis and management of primary biliary cholangitis. Am. J. Gastroenterol. 114(1), 48\u201363 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_9_8_2","unstructured":"URSO 250 and URSO Forte. Ursodiol [Internet]. (2023)."},{"key":"e_1_3_9_9_2","unstructured":"Ocaliva. obeticholic acid [Internet]. (2022). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207999s008lbl.pdf"},{"key":"e_1_3_9_10_2","unstructured":"Iqirvo. Elafibranor [Internet]. (2024). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218860s000lbl.pdf"},{"key":"e_1_3_9_11_2","unstructured":"Livdelzi. seladelpar [Internet]. (2024). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217899s000lbl.pdf"},{"key":"e_1_3_9_12_2","article-title":"Primary biliary cholangitis: patient characteristics and the healthcare economic burden in the United States","volume":"72","author":"Gish RG","year":"2020","unstructured":"Gish RG, Law A, Lingohr-Smith M Primary biliary cholangitis: patient characteristics and the healthcare economic burden in the United States. Hepatology 72, AASLD abstract 1259 (2020).","journal-title":"Hepatology"},{"issue":"9","key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/MCG.0000000000001120","article-title":"Factors associated with potential progressive course of primary biliary cholangitis: data from real-world US database","volume":"53","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Stepanova M, Golabi P Factors associated with potential progressive course of primary biliary cholangitis: data from real-world US database. J. Clin. Gastroenterol. 53(9), 693\u2013698 (2019).","journal-title":"J. Clin. Gastroenterol."},{"issue":"1","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.30174","article-title":"Primary biliary cholangitis in Medicare population: the impact on mortality and resource use","volume":"69","author":"Sayiner M","year":"2019","unstructured":"Sayiner M, Golabi P, Stepanova M Primary biliary cholangitis in Medicare population: the impact on mortality and resource use. Hepatology 69(1), 237\u2013244 (2019).","journal-title":"Hepatology"},{"issue":"3","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/hep4.1314","article-title":"Burden of primary biliary cholangitis among inpatient population in the United States","volume":"3","author":"Shahab O","year":"2019","unstructured":"Shahab O, Sayiner M, Paik J Burden of primary biliary cholangitis among inpatient population in the United States. Hepatol. Commun. 3(3), 356\u2013364 (2019).","journal-title":"Hepatol. Commun."},{"key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"k2817","DOI":"10.1136\/bmj.k2817","article-title":"Mortality due to cirrhosis and liver cancer in the United States, 1999\u20132016: observational study","volume":"362","author":"Tapper EB","year":"2018","unstructured":"Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999\u20132016: observational study. Br. Med. J. 362, k2817 (2018).","journal-title":"Br. Med. J."},{"key":"e_1_3_9_17_2","unstructured":"Komodo Health. Komodo's Healthcare Map\u2122. Komodo Health adds 90M closed lives per year to expansive Healthcare Map. Available from: https:\/\/www.komodohealth.com\/news\/komodo-health-adds-90m-closed-lives-per-year-to-expansive-healthcare-map"},{"key":"e_1_3_9_18_2","unstructured":"Komodo Health. Komodo's Healthcare Map\u2122. Komodo Health platform accelerates real-world evidence for life sciences. Available from: https:\/\/www.komodohealth.com\/news\/komodo-health-platform-accelerates-real-world-evidence-for-life-sciences"},{"issue":"4","key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1055\/a-1910-4154","article-title":"Real-world matching performance of deidentified record-linking tokens","volume":"13","author":"Bernstam EV","year":"2022","unstructured":"Bernstam EV, Applegate RJ, Yu A Real-world matching performance of deidentified record-linking tokens. Appl. Clin. Inform. 13(4), 865\u2013873 (2022).","journal-title":"Appl. Clin. Inform."},{"key":"e_1_3_9_20_2","unstructured":"Optum. Optum\u00ae Clinformatics\u00ae Data Mart. Available from: https:\/\/www.optum.com\/en\/business\/life-sciences\/real-world-data\/claims-data.html"},{"issue":"3","key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1155\/2010\/237860","article-title":"Validation of coding algorithms for the identification of patients with primary biliary cirrhosis using administrative data","volume":"24","author":"Myers RP","year":"2010","unstructured":"Myers RP, Shaheen AA, Fong A Validation of coding algorithms for the identification of patients with primary biliary cirrhosis using administrative data. Can. J. Gastroenterol. 24(3), 175\u2013182 (2010).","journal-title":"Can. J. Gastroenterol."},{"issue":"10","key":"e_1_3_9_22_2","doi-asserted-by":"crossref","first-page":"e70013","DOI":"10.1002\/pds.70013","article-title":"Identifying patients with primary biliary cholangitis and cirrhosis using administrative data in a national cohort","volume":"33","author":"John BV","year":"2024","unstructured":"John BV, Bastaich D, Dahman B. Veterans Analysis of Liver Disease Group of I. Identifying patients with primary biliary cholangitis and cirrhosis using administrative data in a national cohort. Pharmacoepidemiol. Drug Saf. 33(10), e70013 (2024).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"5","key":"e_1_3_9_23_2","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MCG.0b013e3182688d2f","article-title":"Use of administrative claims data for identifying patients with cirrhosis","volume":"47","author":"Nehra MS","year":"2013","unstructured":"Nehra MS, Ma Y, Clark C Use of administrative claims data for identifying patients with cirrhosis. J. Clin. Gastroenterol. 47(5), e50\u201354 (2013).","journal-title":"J. Clin. Gastroenterol."},{"issue":"1","key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor KD","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 69(1), 394\u2013419 (2019).","journal-title":"Hepatology"},{"issue":"4","key":"e_1_3_9_25_2","first-page":"188","article-title":"Charlson Comorbidity Index: ICD-9 update and ICD-10 translation","volume":"12","author":"Glasheen WP","year":"2019","unstructured":"Glasheen WP, Cordier T, Gumpina R Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Am. Health Drug Benefits 12(4), 188\u2013197 (2019).","journal-title":"Am. Health Drug Benefits"},{"issue":"2","key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s10620-019-05809-x","article-title":"Race\/ethnicity and insurance-specific disparities in in-hospital mortality among adults with primary biliary cholangitis: analysis of 2007\u20132014 national inpatient sample","volume":"65","author":"Galoosian A","year":"2020","unstructured":"Galoosian A, Hanlon C, Tana M, Cheung R, Wong RJ. Race\/ethnicity and insurance-specific disparities in in-hospital mortality among adults with primary biliary cholangitis: analysis of 2007\u20132014 national inpatient sample. Dig. Dis. Sci. 65(2), 406\u2013415 (2020).","journal-title":"Dig. Dis. Sci."},{"key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"46958019838118","DOI":"10.1177\/0046958019838118","article-title":"Medicaid patients have greater difficulty scheduling health care appointments compared with private insurance patients: a meta-analysis","volume":"56","author":"Hsiang WR","year":"2019","unstructured":"Hsiang WR, Lukasiewicz A, Gentry M Medicaid patients have greater difficulty scheduling health care appointments compared with private insurance patients: a meta-analysis. Inquiry 56, 46958019838118 (2019).","journal-title":"Inquiry"},{"issue":"2","key":"e_1_3_9_28_2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/hep.31776","article-title":"Male sex is associated with higher rates of liver-related mortality in primary biliary cholangitis and cirrhosis","volume":"74","author":"John BV","year":"2021","unstructured":"John BV, Aitcheson G, Schwartz KB Male sex is associated with higher rates of liver-related mortality in primary biliary cholangitis and cirrhosis. Hepatology 74(2), 879\u2013891 (2021).","journal-title":"Hepatology"},{"issue":"5","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s10620-020-06402-3","article-title":"Gender and racial differences in hospitalizations for primary biliary cholangitis in the USA","volume":"66","author":"Adejumo AC","year":"2021","unstructured":"Adejumo AC, Akhtar DH, Dennis BB Gender and racial differences in hospitalizations for primary biliary cholangitis in the USA. Dig. Dis. Sci. 66(5), 1461\u20131476 (2021).","journal-title":"Dig. Dis. Sci."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T11:46:31Z","timestamp":1742557591000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.57264\/cer-2024-0174"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0174","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"article-number":"e240174"}}